The innovative drug APH04935 tablets of the subsidiary of Poinsettia (300723.SZ) obtained US FDA clinical trial approval

Zhitongcaijing · 3d ago

Zhitong Finance App News, Yipinhong (300723.SZ) issued an announcement. Recently, Guangzhou Yipinhong Pharmaceutical Co., Ltd. (“Yipinhong Pharmaceutical”), a wholly-owned subsidiary of the company, received a letter from the US Food and Drug Administration (FDA) agreeing to the clinical trial of the innovative drug APH04935 tablets independently developed by the company's subsidiary.

APH04935 tablets are a highly active and highly selective small-molecule GLP-1R (full name: Glucagon-like Peptide-1 Receptor, Chinese translation: glucagon-like peptide-1 receptor) agonist independently developed by the company. The goal is to become an oral small molecule GLP-1R agonist administered once a day, intended for weight control and long-term weight loss management.